Signed LOI to acquire 100% interest in chain of specialty addiction pharmacies in Vancouver, BC Acquisition price of $4.0 million based upon approximately 4.7x trailing 6 months annualized EBITDA of $850,000 The chain operates 3 locations, which will be added to the Levitee Pharmacies growing portfolio of locations throughout Alberta and British Columbia Levitee Labs Inc. an integrative wellness company with a ...
  • Signed LOI to acquire 100% interest in chain of specialty addiction pharmacies in Vancouver, BC
  • Acquisition price of $4.0 million based upon approximately 4.7x trailing 6 months annualized EBITDA of $850,000
  • The chain operates 3 locations, which will be added to the Levitee Pharmacies growing portfolio of locations throughout Alberta and British Columbia

Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7) (the "Company" or "Levitee"), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, has signed a letter of intent ("LOI") to acquire 100% of the issued and outstanding shares in a company owning and operating a chain of specialty addiction pharmacies located throughout the lower mainland of British Columbia, Canada.

The chain of pharmacies presently operates in 3 locations throughout the lower mainland, which will be brought under the Levitee Pharmacies umbrella subsequent to the closing of the acquisition.

The acquisition price of $4.0 million is based upon approximately 4.7x trailing 6 months annualized EBITDA (earnings before interest, taxes, depreciation, and amortization). Levitee Labs will pay $2.0 million in cash and $1.2 million in shares of Levitee Labs stock at the closing of the transaction (the "Closing"). The shares have selling restrictions with 25% being released at 4, 6, 8, and 10 months following closing. The remaining $0.8 million will be paid 12 months after the Closing and is structured to incentivize a smooth transition in ownership. This LOI is non-binding and remains subject to the drafting of definitive agreements, approval from Levitee Labs' board, and regulatory body approvals, and confirmatory due diligence.

"This acquisition is our first move into our home province of British Columbia, a province where the opioid epidemic and addiction has been a major visible problem for decades," said Ken Osborne, Head of Mergers & Acquisitions at Levitee Labs. "Our team is excited to make a positive impact by combating this problem so close to home."

"We have grown tremendously since closing multiple acquisitions in July that positioned us with a formidable footprint of clinics and pharmacies in Alberta," said Pouya Farmand, Chief Executive Officer at Levitee Labs. "This is our second largest acquisition to date and provides us a solid foundation to build upon in British Columbia, as we establish the Levitee Labs name as a dominant player in treating patients suffering from addiction and substance use disorder throughout Western Canada. Our M&A team remains active in identifying other opportunities as we continue building momentum and value into the new year."

Levitee expects to fund this acquisition using current cash reserves.

About Levitee Labs Inc.

Levitee is establishing itself as a leader in the integrative wellness space. Through leveraging an M&A regimen that focuses on the centralization of complementary integrative wellness assets, Levitee aims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies. The Company's current portfolio of assets includes: Levitee Clinics™, a group of five operating addiction and pain treatment clinics in Alberta; Levitee Pharmacies™, three pharmacies operating in Alberta specialized in filling prescriptions for patients with substance use disorders, mental health conditions, and chronic pain; BlockMD, the first technology company in Alberta to receive provincial approval for electronic-prescriptions in the addiction treatment space; and Earth Circle Organics, a direct-to-consumer and wholesaler of supplements and superfood products with 180+ SKUs in its product lineup across three brands. Further information about Levitee is available on its website at .

Forward-Looking Statements

This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance, or achievements that Levitee anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Such information may involve, but is not limited to, statements respecting Levitee's business plans and proposed products, and the benefits derived from mushroom-infused products; the expected use of proceeds from the Loan; the acquisitive growth potential of Levitee once acquisitions are completed; the expectation that Levitee will continue to execute its accretive acquisition program, and the contribution of such program to Levitee's future growth potential; the closing of Tranche 1, including the Levitee's ability to satisfy the Tranche 1 closing conditions; the closing of any future tranches under the Loan, including Levitee's ability to satisfy the closing conditions for future tranches of the Loan; and Levitee's objective to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results "may", "could", "would", "might" or "will" (or other variations of the forgoing) be taken, occur, be achieved, or come to pass. These statements and other forward-looking information are based on assumptions made by Levitee based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release as well as management's current expectations or beliefs regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenditures. These assumptions may also be based on information obtained from third-party industry analysts and other third-party sources. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Levitee as of the date such statements are made, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to risks associated with the following: Levitee's limited history of operations; ability to secure additional financing; negative cash flow from operating activities since inception; regulatory requirements; changes in consumer preferences; supply of raw materials; reliance on a limited number of products; brand awareness; the ability to develop, market and produce new products; dependence on certain key senior managers; reliance on third parties for manufacturing and packaging; potential product liability claims and product recalls; and significant competition. For additional information regarding these risks, please see the risk factors identified and reported in Levitee's public filings under its SEDAR profile at Any and all forward-looking information contained in this press release is expressly qualified by this cautionary statement. Readers are cautioned not to place undue reliance on forward-looking statements or information. The forward-looking information is made as of the date of this news release, and Levitee assumes no obligation to publicly update or revise such forward-looking information, except as required by applicable securities laws. The CSE (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release and accepts no responsibility for the adequacy or accuracy hereof.

For further information about Levitee Labs Inc., please contact:

Media Contact:

Investor and Corporate Communications:

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

COMPASS Pathways to participate in upcoming Evercore, H.C. Wainwright & Berenberg investor conferences

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three investor conferences as follows:

  • Evercore ISI 4 th Annual HEALTHCONx Virtual Conference: fireside chat at 9:40am ET on 1 December 2021. The fireside chat will feature Augustus John Rush MD, Adjunct Professor in the Department of Psychiatry and Behavioral Sciences at Duke University School of Medicine

  • H.C. Wainwright 2nd Annual Psychedelics Conference: panel "Three Forms of Psilocybin" at 10:00am ET on 6 December 2021 and presentation available on demand

  • Berenberg European Conference 2021: virtual one-on-one meetings on 8 December 2021

A live audio webcast of the Evercore fireside chat and the H.C. Wainwright presentation will be available on the "Events" page of the Investors section of the COMPASS website. A replay of the webcast will be available for 30 days following each event. For more information, please visit

Keep reading... Show less
Awakn Life Sciences Strengthens Executive Leadership Team

Awakn Life Sciences Strengthens Executive Leadership Team

Kate Butler to Be Appointed CFO; Jonathan Held, Current CFO, to Be Appointed Chief Business Officer

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn' or the 'Company'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today the execution of an agreement to appoint Kate Butler as new Chief Financial Officer ("CFO"), and Jonathan Held, current Chief Financial Officer, to transition to Awakn's Chief Business Officer. Under the terms of the agreement, Kate has joined Awakn effective immediately, however, Jonathan Held shall remain as the CFO for a transition period of up to three months (or such shorter period as may be agreed by the parties), upon which Kate and Jonathan shall each assume their new roles.

Keep reading... Show less

Hollister Biosciences Announces Third Quarter Fiscal 2021 Financial Results Including Revenue of USD $14.5M and Adjusted Ebitda of USD $1.2M

Revenue of $14.5 million increased 53% from prior year period

Gross profit income of $3.5 million increased 151% from prior year period

Keep reading... Show less

iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products

  • iX Biopharma will receive an initial US$9 million upfront payment
  • Eligible for up to US$239 million in development and sales milestone payments
  • Double digit royalties on future product sales of any licensed product

IX Biopharma Ltd (SGX:42C), a specialty pharmaceutical company that develops innovative therapies using its proprietary sublingual drug delivery technology, WaferiX, announced today that it has, through its subsidiary, entered into an exclusive license agreement with Seelos Therapeutics, Inc ("Seelos") (Nasdaq: SEEL), a company focused on developing novel therapeutics for central nervous systems disorders. Under the agreement, iX Biopharma will license to Seelos its lead drug under development, Wafermine, a sublingual racemic ketamine wafer, and other products incorporating R- and S- enantiomers of ketamine utilising the WaferiX technology (the "Licensed Products").

Keep reading... Show less
Stocks2Watch's Virtual Investor Luncheon Agenda Updated for Tuesday November 30

Stocks2Watch's Virtual Investor Luncheon Agenda Updated for Tuesday November 30

Stocks2Watch Investor Series today announced their agenda is updated for the Virtual Investor Luncheon on Tuesday November 30. Individual investors, finance professionals, and analysts are invited to register now to attend the Luncheon.


Keep reading... Show less

What Does the FDA Think About Psychedelics?

The development of the psychedelics industry depends on myriad factors, but one of the most critical is its relationship with a principal medical authority.

The US Food and Drug Administration (FDA) is the leading authority for drug approvals in the US. This federal body determines whether medical products will ultimately reach the hands of patients.

The FDA reviews the clinical data created by established medical studies evaluating the feasibility of drug compounds or products as treatments for specific ailments.

Keep reading... Show less

Top News

Related News